Oncology

Glecaprevir is a NS3/4A protease inhibitor and pibrentasvir is a NS5A inhibitor for hepatitis C patients without cirrhosis.

Glecaprevir/pibrentasvir is indicated as an eight-week treatment for hepatitis C among patients without cirrhosis.

Histone H3 protein is abnormal or incorrectly modified in 15% of patients with head and neck cancer.

High consumption of grilled, barbequed, or smoked meats may increase morality risk in breast cancer survivors.

Study confirms safety and efficacy of Lu-177-PSMA-17 radioligand therapy for metastatic castration-resistant prostate cancer.

A drug developed to treat cardiogenic shock may treat patients with triple negative breast cancer.

BRCA2-inherited prostate cancers are predisposed to turn treatment resistant.

A personalized vaccine may effectively treat HER2-postive breast cancer.

Capsaicin derived from chili peppers shows promise on cultured triple-negative breast cancer cells.

Driven by the graying of America, more than 75% of all newly diagnosed cancers occur in people aged 55 or older. Oncology—and oncology pharmacists—are changing hats swiftly.

Identified cancer driver may be key to increasing survival in metaplastic breast cancer patients.

Immune checkpoint blockade and gene therapy more effective together than alone in brain cancer.

Oncology pharmacists play an important role in the delivery of care to patients living with cancer.

Top news of the week in oncology and cancer drug development.

LJ is a 75-year-old patient with advanced breast cancer. She also has a medical history of hypertension and dementia. LJ decided to stop chemotherapy 2 months ago due to severe nausea, vomiting, and diarrhea.

New at-risk group for skin cancer identified.

Americans living in rural areas more likely to die from top 5 causes of death, including cancer.

The novel tool will be integrated into the National Cancer Institute’s current risk assessment tool.

A $1 million competition announced with a goal of reducing lung cancer deaths by 20%.

Higher intake of grilled, barbecued, and smoked meats increases mortality risk among cancer survivors.

MYL-14010 is designed to treat certain types of human epidermal growth factor receptor 2 (HER2) positive breast cancers.

Investigational treatment for scleroderma autoimmune disease shows high efficacy in melanoma patients.

Systemic chemotherapy combined with immunotherapy negatively impacts the immune system compared with local chemotherapy plus immunotherapy.

Top news of the day from across the healthcare landscape.

In 2015, there were 17.5 million cases of cancer worldwide and 8.7 million cancer-related deaths.

Atezolizumab being examined as first-line treatment for individuals ineligible for cisplatin chemotherapy.

Combination approach better targets breast cancer tumors with PIK3CA gene mutations.

Top news of the week in oncology and cancer drug development.